Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Share-based Compensation (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of Share-based Compensation readings, the most recent being $6.3 million for Q1 2026.

  • On a quarterly basis, Share-based Compensation rose 7.01% to $6.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $25.2 million, a 26.87% increase, with the full-year FY2025 number at $24.8 million, up 11.36% from a year prior.
  • Share-based Compensation hit $6.3 million in Q1 2026 for Catalyst Pharmaceuticals, up from $5.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $8.2 million in Q1 2024 to a low of $1.9 million in Q1 2022.
  • Median Share-based Compensation over the past 5 years was $4.4 million (2024), compared with a mean of $4.4 million.
  • Biggest five-year swings in Share-based Compensation: soared 185.2% in 2024 and later decreased 29.07% in 2025.
  • Catalyst Pharmaceuticals' Share-based Compensation stood at $1.9 million in 2022, then skyrocketed by 120.66% to $4.2 million in 2023, then grew by 21.67% to $5.2 million in 2024, then rose by 9.48% to $5.7 million in 2025, then rose by 10.58% to $6.3 million in 2026.
  • The last three reported values for Share-based Compensation were $6.3 million (Q1 2026), $5.7 million (Q4 2025), and $5.7 million (Q3 2025) per Business Quant data.